Notice ID: 1246821562cd465d800f88e83a937130Special Notice
Naloxone and compounded pharmaceuticals
Archived. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 10:00 AM UTC−06:00
- Posted
- December 15, 2021
- Notice type
- Special Notice
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDepartment of the Army
Notice details
- Office
- W40M MRC0 WEST
- Place of performance
- JBSA Ft Sam Houston, TX, 78234
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- W81K0022Q0012
- Notice ID
- 1246821562cd465d800f88e83a937130
Description
Regional Health Contracting Office-Central, Joint Base San Antonio-Fort Sam Houston, Texas intends to award a sole source contract to Wells Pharma of Houston, LLC. for Naloxone and compounded pharmaceuticals. Naloxone and compounded pharmaceuticals must meet the below salient characteristics: Naloxone 1mg/mL 2mL Oral Syringe Will contain a solution of Naloxone 1mg/ml packaged in 2mL oral syringe Will be packaged in an oral syringe with a tamper evident cap and without a luer lock tip Will be labeled for oral use only Must have a Beyond Use Date of no less than 30 days Ketamine 10mg/mL in Normal Saline 5mL in 10mL OR Syringe Will contain ketamine 10mg/mL mixed with Normal Saline 5mL packaged in a 10mL OR syringe Will have a label affixed to each syringe specifying the contents Must have a Beyond Use Date of no less than 30 days Ketamine 10mg/mL in Normal Saline 10mL in 10mL OR Syringe Will contain ketamine 10mg/mL mixed with Normal Saline 10mL packaged in a 10mL OR syringe Will have a label affixed to each syringe specifying the contents Must have a Beyond Use Date of no less than 30 days Norepinephrine 4mg in D5W 250mL bag Will contain norepinephrine 4mg added to 250mL bag of dextrose 5% in water Will have a label affixed to each bag specifying the contents Must have a Beyond Use Date of no less than 30 day Norepinephrine 8mg in D5W 250mL bag Will contain norepinephrine 8mg added to 250mL bag of dextrose 5% in water Will have a label affixed to each bag specifying the contents Must have a Beyond Use Date of no less than 30 days Award will be made on or about 23 December 2021. The primary NAICS code for the requirement 325412 with a size standard of 1,250 employees. This notice is neither a request for quotes nor a solicitation of offers; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency for future requirements.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
W81K0022Q0012- Market Research
- Market ResearchDec 6, 2021
Naloxone and compounded pharmaceuticals
- Special NoticeCurrentDec 15, 2021
Naloxone and compounded pharmaceuticals
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer. | - | Awarded | Open |
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice. | - | Special Notice | 10/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 10/26/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 08/27/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | - | Solicitation | 10/01/2026 |
Additional Details
Solicitation Number
W81K0022Q0012
Archive Date
Not specified
Office Address
JBSA FT SAM HOUSTON, TX, 78234-4504